Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

Vaccine

Volumn 33, Issue 46, 2015, Pages 6351-6359

  Rupp, Richard ^a   Luckasen, Gary Joseph ^b   Kirstein, Judith Lee ^c   Osorio, Jorge E ^d,g   Santangelo, Joseph D ^e   Raanan, Marsha ^f   Smith, Mary Kathryn ^g   Wallace, Derek ^e   Gordon, Gilad S ^h   Stinchcomb, Dan T ^g  

^a University of Texas Medical Branch School of Medicine   (United States)

^b South Medical Office Building   (United States)

^c Advanced Clinical Research Utah   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Takeda Vaccines Pte Ltd   (Singapore)

^f TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^g Takeda Vaccines   (United States)

^h Orra Group LLC   (United States)

Author keywords

Clinical trial; Dose titration; Immunogenicity; Live attenuated tetravalent dengue vaccine; Multiple administration; Recombinant chimeric dengue vaccine; Safety

Indexed keywords

DENGUE VACCINE; SODIUM CHLORIDE; VIRUS RNA; LIVE VACCINE; PLACEBO;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROTYPE; UNITED STATES; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; NORMAL HUMAN; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; DENGUE; DENGUE VACCINES; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PLACEBOS; UNITED STATES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84946606951     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.008     Document Type: Article

References (20)

1. World Health Organization Dengue: guidelines for diagnosis, treatment, prevention and control 2009, Available at:, (accessed on: 5 May 2015). http://books.google.com.sg/books?hl=en%26lr=%26id=dlc0YSIyGYwC%26oi=fnd%26pg=PP2%26dq=dengue+anticoagulant+treatment%26ots=OMuWEB5Im7%26sig=_hMVWYfaCifFx-IoAtNWy3SJBw.
2. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
3. Halstead S.B., Suaya J.A., Shepard D.S. The burden of dengue infection. Lancet 2007, 369:1410-1411.
4. WHO Global Strategy for dengue prevention and control, 2012-2020 2012, (WHO/HTM/NTD/VEM/2012.5).
5. Schwartz L.M., Halloran M.E., Durbin A.P., Longini I.M. The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine 2015, 33:3293-3298.
6. Hammond S.N., Balmaseda A., Perez L., Tellez Y., Saborio S.I., Mercado J.C., et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 2005, 73:1063-1070.
7. van der Schaar H.M., Wilschut J.C., Smit J.M. Role of antibodies in controlling dengue virus infection. Immunobiology 2009, 214:613-629.
8. Halstead S.B., Heinz F.X., Barrett A.D., Roehrig J.T. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine 2005, 23:849-856.
9. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8:S7-S16.
10. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29:7251-7260.
11. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003, 77:11436-11447.
12. Huang C.Y., Kinney R.M., Livengood J.A., Bolling B., Arguello J.J., Luy B.E., et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis 2013, 7:e2243.
13. Osorio J.E., Velez I.D., Thomson C., Lopez L., Jimenez A., Haller A.A., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, Phase 1 study. Lancet Infect Dis 2014, 14:830-838.
14. George S.L., Wong M.A., Dube T.J.T., Boroughs K.L., Stovall J.L., Luy B.E., et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naïve adults: a randomized, double-blind Phase I clinical trial. Journal of Infectious Diseases 2015, 10.1093/infdis/jiv179.
15. Osorio J.E., Brewoo J.N., Silengo S.J., Arguello J., Moldovan I.R., Tary-Lehmann M., et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011, 84:978-987.
16. Anderson K.B., Gibbons R.V., Edelman R., Eckels K.H., Putnak R.J., Innis B.L., et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011, 204:442-450.
17. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80:302-311.
18. Ambuel Y., Young G., Brewoo J.N., Paykel J., Weisgrau K.L., Rakasz E.G., et al. A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates. Front Immunol 2014, 5:263.
19. U.S.Department of Health and Human Services NIoH, National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 4.03.2 2009.
20. Food and Drug Administration Center for Biologics Evaluation and Research Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 2007, FDA, Maryland.